rs117461552
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6_Very_StrongBS2_Supporting
The NM_206933.4(USH2A):c.6683T>A(p.Val2228Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000232 in 1,613,966 control chromosomes in the GnomAD database, including 3 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Consequence
NM_206933.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
USH2A | NM_206933.4 | c.6683T>A | p.Val2228Glu | missense_variant | 35/72 | ENST00000307340.8 | NP_996816.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
USH2A | ENST00000307340.8 | c.6683T>A | p.Val2228Glu | missense_variant | 35/72 | 1 | NM_206933.4 | ENSP00000305941.3 | ||
USH2A | ENST00000674083.1 | c.6683T>A | p.Val2228Glu | missense_variant | 35/73 | ENSP00000501296.1 |
Frequencies
GnomAD3 genomes AF: 0.000322 AC: 49AN: 152060Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000510 AC: 128AN: 251052Hom.: 0 AF XY: 0.000405 AC XY: 55AN XY: 135670
GnomAD4 exome AF: 0.000224 AC: 327AN: 1461788Hom.: 3 Cov.: 31 AF XY: 0.000224 AC XY: 163AN XY: 727190
GnomAD4 genome AF: 0.000315 AC: 48AN: 152178Hom.: 0 Cov.: 32 AF XY: 0.000403 AC XY: 30AN XY: 74382
ClinVar
Submissions by phenotype
not specified Benign:2
Benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | May 07, 2012 | Val2228Glu in Exon 35 of USH2A: This variant is not expected to have clinical si gnificance because it has been identified in 4.2% (5/120) of chromosomes from a population in the dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP; rs11 7461552). - |
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 11, 2022 | Variant summary: USH2A c.6683T>A (p.Val2228Glu) results in a non-conservative amino acid change located in the Fibronectin type III domain (IPR003961) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00051 in 251052 control chromosomes, predominantly at a frequency of 0.0069 within the East Asian subpopulation in the gnomAD database. This frequency is not significantly higher than expected for a pathogenic variant in USH2A causing Usher Syndrome (0.00051 vs 0.011), allowing no conclusion about variant significance. c.6683T>A has been reported in the literature with conflicting interpretations (VUS/Likely Benign) along with other variants in the USH2A gene (phase not specified) in cohorts of individuals undergoing whole exome sequencing (WES) for genetic evaluation of Retinal Degeneration (RD) and in particular with Retinitis Pigmentosa (example, Ma_2021). These report(s) do not provide unequivocal conclusions about association of the variant with Usher Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as benign/likely benign. Based on the evidence outlined above, the variant was classified as likely benign. - |
Usher syndrome type 2A Benign:2
Likely benign, no assertion criteria provided | clinical testing | Natera, Inc. | May 03, 2020 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 04, 2023 | - - |
not provided Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 30, 2024 | - - |
Retinitis pigmentosa 39 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 04, 2023 | - - |
Retinal dystrophy Benign:1
Benign, criteria provided, single submitter | research | Dept Of Ophthalmology, Nagoya University | Oct 01, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at